2486316-20-3
Chemical Structure
ZL006-05
- CAS No.: 2486316-20-3
- Formula:C24H27Cl2NO4
- Molecular Weight:464.38
InChIKey: TYSHAYZVTBEVSY-AQDXNVIQSA-N
SMILES: C[C@]12[C@H](C[C@](CC2)([H])C1(C)C)OC(C3=C(C=C(C=C3)NCC4=C(C(Cl)=CC(Cl)=C4)O)O)=O
Biological Activity: ZL006-05 is an orally active, brain-penetrant nNOS–PSD-95 and α2-containing GABAA dual-target inhibitor. ZL006-05 blocks the nNOS-PSD-95 protein-protein interaction and selectively potentiatesα2-containing GABAA receptors. ZL006-05 attenuates central sensitization and strengthens inhibitory GABAergic synaptic transmission. ZL006-05 can be used for the study of neuropathic pain, cancer pain, chemotherapy-induced peripheral neuropathic pain, ischemic stroke, poststroke depression and anxiety[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZL006-05 | ZL006-05 is an orally active, brain-penetrant nNOS–PSD-95 and α2-containing GABAA dual-target inhibitor. ZL006-05 blocks the nNOS-PSD-95 protein-protein interaction and selectively potentiatesα2-containing GABAA receptors. ZL006-05 attenuates central sensitization and strengthens inhibitory GABAergic synaptic transmission. ZL006-05 can be used for the study of neuropathic pain, cancer pain, chemotherapy-induced peripheral neuropathic pain, ischemic stroke, poststroke depression and anxiety. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. 1. Wei W et al. A Compound Mitigates Cancer Pain and Chemotherapy-Induced Neuropathic Pain by Dually Targeting nNOS-PSD-95 Interaction and GABAA Receptor. Neurotherapeutics. 2021 Oct;18(4):2436-2448. [Content Brief]
- [2]. 2. Li J et al. A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABAARs. Theranostics. 2021 Apr 3;11(12):5970-5985.2. Li J et al. A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABAARs. Theranostics. 2021 Apr 3;11(12):5970-5985.2. Li J et al. A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABAARs. Theranostics. 2021 Apr 3;11(12):5970-5985. [Content Brief]
- [3]. 3. Wu H et al. Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects. Stroke Vasc Neurol. 2023 Dec 29;8(6):463-474. [Content Brief]
